← Back to Search

E-Cigarettes for Smoking in Substance Use Disorders

Phase 2
Recruiting
Led By Scott Sherman, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
report having a history of asthma, other airways diseases, or heart disease.
currently using smoking cessation medications (including other forms of NRT, buproprion, or varenicline)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights

Summary

This trial will test whether e-cigarettes can help patients in addiction treatment quit smoking cigarettes, as they have higher rates of smoking than the general population.

Who is the study for?
This trial is for individuals who smoke at least 10 cigarettes daily, are in addiction treatment, and have had alcohol or opioid use disorder in the past year. Participants must be able to consent, interested in reducing smoking, use a cellphone for daily texts about their smoking and e-cigarette use but not currently using other tobacco products or cessation aids.Check my eligibility
What is being tested?
The study explores if e-cigarettes can help people with substance use disorders reduce harm from smoking. It involves giving participants either real or placebo e-cigarettes and monitoring their cigarette consumption over three weeks to see if there's any change.See study design
What are the potential side effects?
Potential side effects of nicotine replacement therapy like e-cigarettes may include throat irritation, coughing, headache, nausea, and dependency on the product. The exact side effects will depend on individual reactions to using e-cigarettes.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of asthma, airway diseases, or heart disease.
Select...
I am currently using medication to help me stop smoking.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants who achieve 50% reduction in CPD at 3 weeks.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: E cigarettesExperimental Treatment1 Intervention
Group II: Nicotine Replacement TherapyActive Control1 Intervention

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,379 Previous Clinical Trials
847,878 Total Patients Enrolled
Scott Sherman, MDPrincipal InvestigatorNYU Langone Health
4 Previous Clinical Trials
1,089 Total Patients Enrolled

Media Library

E-cigarettes Clinical Trial Eligibility Overview. Trial Name: NCT04063267 — Phase 2
Smoking/Cigarette Smoking Research Study Groups: E cigarettes, Nicotine Replacement Therapy
Smoking/Cigarette Smoking Clinical Trial 2023: E-cigarettes Highlights & Side Effects. Trial Name: NCT04063267 — Phase 2
E-cigarettes 2023 Treatment Timeline for Medical Study. Trial Name: NCT04063267 — Phase 2
~51 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top